James C O'Neil

US Patent:

8410154, Apr 2, 2013

Filed:

Apr 30, 2009

Appl. No.:

12/989724

Inventors:

James Dennen O'Neil - Frederick MD, US
Shalini Sharma - Gaithersburg MD, US
Ramachandran Arudchandran - Germantown MD, US

Assignee:

Wellstat Therapeutics Corporation - Gaithersburg MD

International Classification:

A61K 31/41
C07D 257/04

US Classification:

514381, 548251

Abstract:

Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula I. The uric acid-lowering effects of the compounds of this invention are used to treat or prevent a variety of conditions including gout, hyperuricemia, elevated levels of uric acid that do not meet the levels customarily justifying a diagnosis of hyperuricemia, renal dysfunction, kidney stones, cardiovascular disease, risk for developing cardiovascular disease, tumor-lysis syndrome, cognitive impairment, early-onset essential hypertension, and -induced inflammation. In Formula 1, x is 1 or 2: y is O, 1, 2 or 3; and Ris selected from the group consisting of hydrogen, alkyl having 1 or 2 carbon atoms, hydroxy, alkoxy having 1 or 2 carbon atoms, fluoro, chloro, bromo, and amino. A is phenyl unsubstituted or substituted by one, two or three groups selected from the group consisting of halo, alkyl having 1 or 2 carbon atoms, perfluoromethyL alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloalkyl having from 3 to 6 ring atoms wherein the cycloalky! is unsubstituted or one one two ring carbons are independently mono-substituted by methyl or ethyl; or a 5 or 6 membered heleraromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound by a ring carbon.

US Patent:

20110014176, Jan 20, 2011

Filed:

Mar 13, 2009

Appl. No.:

12/920555

Inventors:

James Dennen O'Neil - Frederick MD, US
Michael K. Bamat - Potomac MD, US
Reid W. von Borstel - Potomac MD, US
Shalini Sharma - Gaithersburg MD, US
Ramachandran Arudchandran - Germantown MD, US

Assignee:

WELLSTAT THERAPEUTICS CORPORATION - Gaithersburg MD

International Classification:

A61K 38/44
A61K 31/192
A61K 31/216
A61K 31/4412
C07C 59/68
A61P 3/00
A61P 19/06
A61P 13/12
A61P 9/00
A61P 25/28
A61P 9/12

US Classification:

424 944, 514570, 514543, 514345, 562471

Abstract:

This invention pertains to the discovery that certain extracts of licorice, particularly when formulated as a candy or lollipop or other means that provides an extended release (e.g., greater than about 4 minutes) to the oral cavity significantly inhibits the formation of dental caries in a human subject.

US Patent:

20120078529, Mar 29, 2012

Filed:

May 11, 2010

Appl. No.:

13/319563

Inventors:

James Dennen O'Neil - Frederick MD, US
Reid W. von Borstel - Potomac MD, US

Assignee:

WELLSTAT THERAPEUTICS CORPORATION - Gaithersburg MD

International Classification:

G06F 19/00
G01N 33/15

US Classification:

702 19

Abstract:

A severity score for 5-fluorouracil (5FU) toxicity is calculated by taking the square root of the sum of: (a) the square of the logarithm of the dose of 5-fluorouracil administered to the patient; and (b) the square of the logarithm of the administration rate of the 5-fluorouracil to the patient.

US Patent:

20120201803, Aug 9, 2012

Filed:

Sep 15, 2011

Appl. No.:

13/501338

Inventors:

Shalini Sharma - Gaithersburg MD, US
James Dennen O'Neil - Frederick MD, US
Reid W. von Borstel - Potomac MD, US
Ramchandran Arudchandran - Germantown MD, US

Assignee:

WELLSTAT THERAPEUTICS CORPORATION - Gaithersburg MD

International Classification:

A61K 38/44
C07C 217/22
C07C 255/58
C07C 255/57
C07C 69/78
C07C 229/60
C07C 69/88
C07C 59/68
C07C 205/42
A61K 31/41
A61K 31/195
A61K 31/275
A61K 31/235
A61K 31/245
A61K 31/192
A61K 31/216
A61P 19/06
C07D 257/04

US Classification:

424 944, 548253, 548252, 562451, 558416, 560109, 560 19, 560 72, 562478, 562435, 562465, 514381, 514567, 514522, 514533, 514570, 514564, 514539

Abstract:

A process for forming a solid electrolytic capacitor and an electrolytic capacitor formed by the process. The process includes: providing an anode wherein the anode comprises a porous body and an anode wire extending from the porous body; applying a thin polymer layer onto the dielectric, and forming a dielectric on the porous body to form an anodized anode; applying a first slurry to the anodized anode to form a blocking layer wherein the first slurry comprises a first conducting polymer with an median particle size of at least 0.05 μm forming a layer of crosslinker on the blocking layer; and applying a layer of a second conducting polymer on the layer of crosslinker.